IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients

Clinical Immunology

Volumn 158, Issue 2, 2015, Pages 174-182

  Ortiz, M A ^a   Diaz Torne C ^a   Hernandez M V ^b   Reina, D ^c   de la Fuente, D ^d   Castellvi I ^e   Moya, P ^a   Ruiz, J M ^d   Corominas, H ^c   Zamora, C ^a   Canto E ^a   Sanmarti R ^b   Juarez, C ^a   Vidal, S ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Servicio de Medicina Intensiva   (Spain)

^d HOSPITAL DE VILADECANS   (Spain)

^e Hospital Comarcal de l'Alt Penedès   (Spain)

Author keywords

IL 6; Leukocytes; Rheumatoid arthritis; STATs; Tocilizumab

Indexed keywords

ANTIBODY; CCP ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; MONOCLONAL ANTIBODY; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; LEUKOCYTES; MIDDLE AGED; PEPTIDES, CYCLIC; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84928614728     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.025     Document Type: Article

References (40)

1. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:1898-1906.
2. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14:397-440.
3. Field M., Chu C., Feldmann M., Maini R.N. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol. Int. 1991, 11:45-50.
4. Houssiau F.A., Devogelaer J.P., Van Damme J., de Deuxchaisnes C.N., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31:784-788.
5. Yoshizaki K., Nakagawa T., Kaieda T., Muraguchi A., Yamamura Y., Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J. Immunol. 1982, 128:1296-1301.
6. Kishimoto T. Interleukin-6: from basic science to medicine-40years in immunology. Annu. Rev. Immunol. 2005, 23:1-21.
7. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 2006, 80:227-236.
8. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334(Pt 2):297-314.
9. Jones G.W., Greenhill C.J., Williams J.O., Nowell M.A., Williams A.S., Jenkins B.J., Jones S.A. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Ann. Rheum. Dis. 2013, 72:1738-1742.
10. Wang F., Sengupta T.K., Zhong Z., Ivashkiv L.B. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J. Exp. Med. 1995, 182:1825-1831.
11. Shouda T., Yoshida T., Hanada T., Wakioka T., Oishi M., Miyoshi K., Komiya S., Kosai K., Hanakawa Y., Hashimoto K., Nagata K., Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 2001, 108:1781-1788.
12. Kasperkovitz P.V., Verbeet N.L., Smeets T.J., van Rietschoten J.G., Kraan M.C., van der Pouw Kraan T.C., Tak P.P., Verweij C.L. Activation of the STAT1 pathway in rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63:233-239.
13. van der Pouw Kraan T.C., van Gaalen F.A., Kasperkovitz P.V., Verbeet N.L., Smeets T.J., Kraan M.C., Fero M., Tak P.P., Huizinga T.W., Pieterman E., Breedveld F.C., Alizadeh A.A., Verweij C.L. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003, 48:2132-2145.
14. Tamai M., Kawakami A., Tanaka F., Miyashita T., Nakamura H., Iwanaga N., Izumi Y., Arima K., Aratake K., Huang M., Kamachi M., Ida H., Origuchi T., Eguchi K. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma through JAK/STAT pathway by translational regulation. J. Lab. Clin. Med. 2006, 147:182-190.
15. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V., Beroukas D., Roberts-Thomson P.J., Smith M.D. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann. Rheum. Dis. 2006, 65:149-156.
16. Kim S., Koga T., Isobe M., Kern B.E., Yokochi T., Chin Y.E., Karsenty G., Taniguchi T., Takayanagi H. STAT1 functions as a cytoplasmic attenuator of RUNX2 in the transcriptional program of osteoblast differentiation. Genes Dev. 2003, 17:1979-1991.
17. Levy C., Nechushtan H., Razin E. A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor. J. Biol. Chem. 2002, 277:1962-1966.
18. Goodman W.A., Young A.B., McCormick T.S., Cooper K.D., Levine A.D. STAT3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 2011, 186:3336-3345.
19. Takeda A., Hamano S., Yamanaka A., Hanada T., Ishibashi T., Mak T.W., Yoshimura A., Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 2003, 170:4886-4890.
20. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008, 2:75-82.
21. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
22. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., Ramiro S., Winthrop K., de Wit M., Aletaha D., Betteridge N., Bijlsma J.W., Boers M., Buttgereit F., Combe B., Cutolo M., Damjanov N., Hazes J.M., Kouloumas M., Kvien T.K., Mariette X., Pavelka K., van Riel P.L., Rubbert-Roth A., Scholte-Voshaar M., Scott D.L., Sokka-Isler T., Wong J.B., van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014, 73:492-509.
23. Tornero Molina J., Sanmarti Sala R., Rodriguez Valverde V., Martin Mola E., Marenco de la Fuente J.L., Gonzalez Alvaro I., Munoz Fernandez S., Gomez-Reino Carnota J., Carreno Perez L., Batlle Gualda E., Balsa Criado A., Andreu J.L., Alvaro-Gracia J.M., Martinez Lopez J.A., Loza Santamaria E. Update of the consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol. Clin. 2010, 6:23-36.
24. van Gestel A.M., Prevoo M.L., van't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International league against rheumatism criteria. Arthritis Rheum. 1996, 39:34-40.
25. Overton W.R. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry 1988, 9:619-626.
26. Diaz-Torne C., Ortiz de Juana M.A., Geli C., Canto E., Laiz A., Corominas H., Casademont J., de Llobet J.M., Juarez C., Diaz-Lopez C., Vidal S. Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis. Immunology 2013, 142:354-362.
27. Karonitsch T., von Dalwigk K., Steiner C.W., Bluml S., Steiner G., Kiener H.P., Smolen J.S., Aringer M. Interferon signals and monocytic sensitization of the interferon-gamma signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 2011, 64:400-408.
28. Yasukawa H., Sasaki A., Yoshimura A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 2000, 18:143-164.
29. Deon D., Ahmed S., Tai K., Scaletta N., Herrero C., Lee I.H., Krause A., Ivashkiv L.B. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J. Immunol. 2001, 167:5395-5403.
30. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., Heinrich P.C., Muller-Newen G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170:3263-3272.
31. Hikasa M., Yamamoto E., Kawasaki H., Komai K., Shiozawa K., Hashiramoto A., Miura Y., Shiozawa S. p21waf1/cip1 is down-regulated in conjunction with up-regulation of c-Fos in the lymphocytes of rheumatoid arthritis patients. Biochem. Biophys. Res. Commun. 2003, 304:143-147.
32. Smiljanovic B., Grun J.R., Biesen R., Schulte-Wrede U., Baumgrass R., Stuhlmuller B., Maslinski W., Hiepe F., Burmester G.R., Radbruch A., Haupl T., Grutzkau A. The multifaceted balance of TNF-alpha and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J. Mol. Med. (Berl.) 2012, 90:1295-1309.
33. van der Pouw Kraan T.C., van Gaalen F.A., Huizinga T.W., Pieterman E., Breedveld F.C., Verweij C.L. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 2003, 4:187-196.
34. Yokota A., Narazaki M., Shima Y., Murata N., Tanaka T., Suemura M., Yoshizaki K., Fujiwara H., Tsuyuguchi I., Kishimoto T. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J. Rheumatol. 2001, 28:1952-1959.
35. Crabe S., Guay-Giroux A., Tormo A.J., Duluc D., Lissilaa R., Guilhot F., Mavoungou-Bigouagou U., Lefouili F., Cognet I., Ferlin W., Elson G., Jeannin P., Gauchat J.F. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 2009, 183:7692-7702.
36. Kamiya S., Okumura M., Chiba Y., Fukawa T., Nakamura C., Nimura N., Mizuguchi J., Wada S., Yoshimoto T. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol. Lett. 2011, 138:47-53.
37. Thiolat A., Semerano L., Pers Y.M., Biton J., Lemeiter D., Portales P., Quentin J., Jorgensen C., Decker P., Boissier M.C., Louis-Plence P., Bessis N. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014, 66:273-283.
38. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., Ornetti P., Maillefert J.F., Miossec P., Bonnotte B. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64:2499-2503.
39. Sarantopoulos A., Tselios K., Gkougkourelas I., Pantoura M., Georgiadou A.M., Boura P. Tocilizumab leads to a rapid and sustained increase of T regulatory cells in rheumatoid arthritis patients. Arthritis Rheumatol. 2014, 66(9):2638.
40. Betts B.C., St Angelo E.T., Kennedy M., Young J.W. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood 2011, 118:5340-5343.